Latest SMC decisions

The Scottish Medicines Consortium (SMC) has released its latest recommendations on the use of medications within NHS Scotland.

The angioedema treatment, Firazyr (icatibant acetate), can be self-administered at home | SCIENCE PHOTO LIBRARY
The angioedema treatment, Firazyr (icatibant acetate), can be self-administered at home | SCIENCE PHOTO LIBRARY


  • icatibant acetate (Firazyr), for the treatment of acute attacks of hereditary angioedema in adults;
  • everolimus (Afinitor), for the treatment of unresectable or metastatic, well- or moderately-differentiated pancreatic neuroendocrine tumours (pNET) in adults with progressive disease.

Suitable for restricted use

  • imatinib (Glivec), for restricted use as adjuvant treatment in patients who are at significant risk of relapse following resection of a KIT (CD117)-positive gastrointestinal stromal tumour (GIST);
  • the collagenase product, Xiapex, for the treatment of moderately severe Dupuytren’s contracture in patients with a palpable cord and up to two affected joints per hand. It is restricted to use as an alternative to limited fasciectomy when percutaneous needle fasciotomy is not considered suitable.


The SMC has rejected applications for the following treatments on the grounds that they do not offer value for money:

  • abiraterone acetate (Zytiga), for castration-resistant prostate cancer;
  • asenapine (Sycrest), for manic episodes in bipolar disorder;
  • belimumab (Benlysta), for systemic lupus erythematosus;
  • bevacizumab (Avastin), for the first-line treatment of metastatic breast cancer when taxanes and anthracyclines are inappropriate, in combination with capecitabine;
  • fingolimod (Gilenya), for relapsing-remitting multiple sclerosis;
  • ipilimumab (Yervoy), for advanced melamona.

In addition, tocilizumab (RoActemra) was rejected as monotherapy for the treatment of moderate to severe active rheumatoid arthritis in adults who have responded inadequately to or who were intolerant of previous therapy, including one or more DMARDs or TNF antagonists, as clinical data supporting the case was poor and data for the cost-benefit analysis contained a number of weaknesses.

Further information: Scottish Medicines Consortium 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases